

1 **A cross-tissue, age-specific flow cytometry reference for immune cells in the airways and**
2 **blood of children**

3 Shivanthan Shanthikumar^{1,2,3}, Liam Gubbels¹, Karen Davies⁴, Hannah Walker^{1,2,5}, Anson Tsz
4 Chun Wong^{1,2}, Jovana Maksimovic^{6,7}, Alicia Oshlack^{6,7,8}, Richard Saffery^{1,2}, Eric Levi^{4,9},
5 Sarath C. Ranganathan^{1,2,3}, Melanie R. Neeland^{1,2}

6 ¹ Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.

7 ² Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia.

8 ³ Respiratory and Sleep Medicine, Royal Children's Hospital, Parkville, VIC, Australia.

9 ⁴ Otolaryngology, Royal Children's Hospital, Parkville, VIC, Australia.

10 ⁵ Children's Cancer Centre, Royal Children's Hospital, Parkville, VIC, Australia.

11 ⁶ Computational Biology Program, Peter MacCallum Cancer Centre, Parkville, VIC, Australia.

12 ⁷ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.

13 ⁸ School of Mathematics and Statistics, University of Melbourne, Parkville, VIC, Australia.

14 ⁹ Clinical Sciences, Murdoch Children's Research Institute, Parkville, VIC, Australia.

15 **ABSTRACT**

16 Respiratory diseases are a common cause of morbidity and hospitalisation for children.
17 Despite this, treatment options are limited and are often ineffective. The development of
18 curative or disease-modifying treatments for children relies on a better understanding of
19 underlying immunity in the early airway. To establish a flow cytometry reference for immune
20 cells in the paediatric airway, we analysed 178 samples from 66 children aged between 1-15
21 years. This included five tissues of the upper (nasal brushings, palatine tonsils, adenotonsil)
22 and lower (bronchial brushings, bronchoalveolar lavage (BAL)) airway, as well as whole
23 blood for paired analysis of local and systemic immune response. Nasal, bronchial, and
24 alveolar samples were analysed using a 17-plex antibody panel that captures cells of immune
25 and epithelial lineage, while tonsil, adenoid, and blood samples were analysed using a 31-
26 plex antibody panel that extensively phenotypes mononuclear immune cells. All protocols,
27 panels, and data are openly available, to facilitate implementation in paediatric clinical
28 laboratories. We provide age-specific cell reference data for infancy (0-2 years), preschool (3-
29 5 years), childhood (6-10 years) and adolescence (11-15 years) for 37 cell populations. We
30 show tissue-specific maturation of the airway immune system across childhood, further
31 highlighting the importance of developing age-specific references of the paediatric airway.
32 Intra-individual, cross-tissue analysis of paired samples revealed marked correlation in
33 immune cell proportions between paired nasal-bronchial samples, paired tonsil-adenoid
34 samples, and paired adenoid-blood samples, which may have implications for clinical testing.
35 Our study advances knowledge of airway immunity from infancy through to adolescence and
36 provides an openly available control dataset to aid in interpretation of clinical findings in
37 samples obtained from children with respiratory diseases.

38 **INTRODUCTION**

39 Respiratory diseases are a major source of morbidity and hospitalisation in children
40 worldwide. They not only cause significant short-term effects but may also have lifelong
41 impacts on lung function ¹. Despite this, treatment options for children are limited, largely
42 extrapolated from adults, and often confer little to no clinical benefit. This is due, in part, to
43 limited understanding of the mechanisms that underly disease in children and a lack of age-
44 specific reference ranges for cells and soluble factors present in the paediatric airway.

45 A lack of age-specific, reliable reference ranges for children extends beyond the respiratory
46 system into all aspects of paediatric health care ^{2, 3}. Many of the available reference intervals
47 were determined over three decades ago using technologies that are no longer relevant in a
48 clinical setting. Despite considerable efforts to address this in recent years, current paediatric
49 reference ranges remain largely incomplete ⁴. The development of age-specific reference
50 ranges is particularly crucial in paediatric respiratory medicine due to the marked age-related
51 differences in susceptibility and immunological response to a range of infectious and chronic
52 conditions of the lung. This was recently highlighted during the COVID-19 pandemic, with
53 children showing a markedly mild manifestation of disease compared to adults ⁵, and is also
54 observed for other conditions including RSV infection ⁶, wheezing, and asthma ⁷. A better
55 understanding of immune cell composition in the healthy paediatric airway may help to
56 identify diagnostic biomarkers of disease, targets for anti-inflammatory therapy, and inform
57 novel interventions such as mucosal vaccination.

58 We aimed to develop a clinically relevant age-specific flow cytometry reference for immune
59 cells in the upper and lower airways of children. Our secondary aims were to explore changes
60 in immune cell composition in the first 15 years of life, understand the relationship between
61 airway and systemic immunity, and discover cross-tissue relationships in immune cell
62 proportions within individuals.

63 **RESULTS**

64 **1. Establishing a clinical reference for immune cells in airways and blood of** 65 **children**

66 To establish a reference for immune cells in the paediatric airway, we sampled five tissues
67 comprising both the upper airway (nasal brushings, palatine tonsils, adenotonsil), and lower
68 airway (bronchial brushings, BAL) from 66 children undergoing general anaesthesia at the
69 Royal Children’s Hospital Melbourne. The clinical indications for these procedures are
70 provided in Supplementary Table 1, with >80% of the cohort undergoing a procedure for
71 obstructive sleep apnoea (OSA). Medical history and information on respiratory status from
72 parent questionnaires are provided in Supplementary Table 2. These children were aged
73 between 1 and 15 years, allowing for age stratification across infancy (0-2 years), preschool
74 period (3-5 years), childhood (6-10 years), and adolescence (11-15 years) (Figure 1A).
75 Furthermore, where possible, multiple airway samples were collected per participant,
76 allowing for intra-individual, cross-tissue assessment of immunity in the upper and lower
77 airway. We also analysed whole blood in order to establish a reference panel of circulating
78 immune cells and to enable associations between the systemic and respiratory immune
79 systems in childhood. Airway and blood samples were processed to single-cell suspensions
80 and analysed by spectral flow cytometry using two multiplexed panels (Figure 1B). The first
81 panel, comprising 17 markers, captures cell populations present in nasal, bronchial, and
82 alveolar samples (Supplementary Table 3). These cell types include those of both immune
83 and epithelial lineage (Figure 1C). The second panel, comprising 31 markers, captures
84 immune cell populations present in the palatine tonsil (“tonsil”), adenotonsil (“adenoid”), and
85 blood samples (Supplementary Table 4). These include all major immune cell populations
86 and their subtypes, with a focus on B- and T- cell lineages given the role of tonsils and
87 adenoids as major lymphoid niches (Figure 1D). We designed publicly available sample
88 processing and flow cytometry protocols (protocols.io/workspaces/earlyAIR) with the goal
89 they could be implemented in paediatric clinical laboratories.

90 **2. Immune cell landscape of paediatric nasal, bronchial, and alveolar samples**

91 Epithelial and immune cell populations were identified in nasal, bronchial, and alveolar
92 samples based on expression of 16 key lineage markers (Figure 2A-C, Supplementary Figure
93 1). Immune cell populations identified were neutrophils, eosinophils, macrophages, NK cells,
94 NK-T cells, CD8 T cells, CD4 T cells, B cells, monocytes, and conventional dendritic cells

95 (cDCs). In all compartments, the immune cell lineage outnumbered the epithelial lineage,
96 particularly more distally through the airway (Figure 2D-F). In nasal samples, immune cells
97 comprised a median of 74.3% of all cells, bronchial samples 88%, and alveolar samples 98%
98 (Figure 2D-F). Median proportions of the 10 major immune cell subtypes in each sample type
99 are shown in Figure 2G-I. To help develop age-specific references for each of these tissues,
100 the median and range of each cell population are reported by clinically relevant age groups
101 (all ages (age 1-15 years), infancy (0-2 years), preschool (3-5 years), childhood (6-10 years),
102 adolescence (11-15 years)) and presented in Tables 1-3. For nasal samples, all five age
103 analyses are reported (Table 1). For bronchial and alveolar samples, due to more limited
104 numbers, a subset of these age groups is reported (Tables 2-3).

105 **3. Immune cell landscape of paediatric tonsil, adenoid, and blood samples.**

106 Immune cell populations were identified in tonsil, adenoid and whole blood samples based on
107 expression of 22 lineage markers (Figure 3A-C, Supplementary Figure 2). In tonsils and
108 adenoids, 25 immune cell populations were quantified, and in whole blood 30 immune cell
109 populations were quantified. Additional populations observed in blood that were not observed
110 in tonsil/adenoid tissue include eosinophils, CD56^{bright} subsets of NK cells and subsets of
111 CD16 expressing monocytes including non-classical and intermediate monocytes. On the
112 other hand, germinal centre (GC) B cells, one of the most abundant populations in tonsils and
113 adenoids, were not observed in blood. Mean Fluorescence Intensity (MFI) analysis of marker
114 expression revealed differential surface receptor patterns across the three compartments
115 including: CD24 expression on NK and NK-T cells from adenoid and tonsil tissue that is not
116 observed on the respective blood populations; high expression of CD38 on T cell populations
117 in tissue: and CXCR5 expression NK-T cells in tissue (Figure 3A-C). Median proportions of
118 immune cell populations in all tonsil, adenoid, and blood samples are shown in Figure 3D-F,
119 respectively. To help develop age-specific references for each of these tissues, the median and
120 range of each cell population are reported by clinically relevant age groups (all ages, infancy,
121 preschool, childhood, adolescence) and presented in Tables 4-6.

122 **4. Airway and blood immune cell dynamics over the first 15 years of life**

123 To identify age-specific cellular associations, we performed two-tailed spearman correlation
124 analyses on cell proportion data in each tissue from children aged 1-15 years. No significant
125 age associations for immune cell populations were seen in nasal or alveolar samples after
126 correction for the false discovery rate. In contrast, for bronchial samples, macrophages and

127 NK-T cells increased with age (spearman coefficient (ρ)=0.80, FDR-P=0.002; ρ =0.63, FDR-
128 P=0.03, respectively) while a subset of neutrophils expressing intermediate levels of
129 activation marker CD66b and high levels of CD16 reduced with age (ρ = -0.71, FDR-P=0.01)
130 (Figure 4A). In tonsil samples, transitional B cells decreased with age (ρ = -0.62, FDR-
131 P=0.002), while classical memory B cells, CD8 TEM cells and CD4 Thelper cells increased
132 with age (ρ =0.51, FDR-P=0.02; ρ =0.47, FDR-P=0.04; ρ =0.63, FDR-P=0.002, respectively)
133 (Figure 4B). The same associations with age were also observed in adenoid samples, where
134 transitional B cells decreased with age (ρ = -0.51, FDR-P=0.007) and classical memory B
135 cells, CD8 TEM and CD4 Thelper cells increased with age (ρ =0.43, FDR-P=0.02; ρ =0.52,
136 FDR-P=0.006; ρ =0.62, FDR-P=0.0008, respectively) (Figure 4C). Additionally, four other
137 adenoid immune cells were also associated with age. These were GC B cells and T follicular
138 helper (TFH) cells which decreased with age (ρ = -0.41, FDR-P=0.03; ρ = -0.42, FDR-P=0.02,
139 respectively), and non-switched memory B cells and NK-T cells which increased with age
140 (ρ =0.69, FDR-P=0.0008; ρ =0.62, FDR-P=0.0008, respectively) (Figure 4C). Like the tonsil
141 and adenoid tissue, blood transitional B cells, NK- T cells, and CD4 Thelper cells were also
142 associated with age (ρ = -0.52, FDR-P=0.001; ρ =0.47, FDR-P=0.005; ρ =0.44, FDR-P=0.009,
143 respectively) (Figure 4D). Blood neutrophils increased with age (ρ = 0.40, FDR-P=0.02),
144 while intermediate monocytes and cDCs decreased with age (ρ = -0.42, FDR-P=0.01; ρ = -
145 0.38, FDR-P=0.02) (Figure 4D). Blood CD4 TN cells decreased with age (ρ =-0.34, FDR-
146 P=0.049) and CD8 TEM cells also tended to increase with age (ρ =0.31, raw-P=0.04, FDR-
147 P=0.09). Individual dot plots depicting correlations for each significant cell type in each
148 tissue are presented in Supplementary Figures 3 and 4.

149 These results demonstrate maturation of the airway immune system with age, centred around
150 the development of memory B cells, memory CD8 T cells, and CD4 T effector populations.
151 Notably, NK-T cell proportions were also highly dynamic, increasing significantly with age
152 in three locations (bronchial, adenoid, and blood) as well as in the alveolar region albeit not
153 significantly when correcting for FDR (ρ =0.88, raw-P=0.007, FDR-P=0.1).

154 **5. Cross-tissue analysis of cell type proportions in the upper and lower airway**

155 We next directly compared the composition of immune cells across nasal, bronchi, and
156 alveolar regions. As can be seen in Figure 5A, cell type proportions vary throughout the
157 airway, with granulocytes (neutrophils and eosinophils) more highly abundant in nasal and
158 bronchial tissues; a progressive increase in the proportions of macrophages down the airway;

159 and a shift from CD8 T cell dominance in nasal samples to more equal CD8:CD4 T cell ratios
160 in the alveolar region. Cross-sectional statistical analysis showed that proportions of
161 granulocytes were significantly higher in both the nasal and bronchial samples when
162 compared to alveolar samples (Figure 5B). Macrophage proportions were significantly higher
163 in bronchial compared to nasal, in alveolar compared to nasal, and in alveolar compared to
164 bronchial samples (Figure 5B). Regarding lymphocytes, CD8 T cells and B cells were
165 significantly higher in the nasal than the alveolar samples, and NK-T cells were significantly
166 lower in nasal samples when compared to bronchial samples (Figure 5B). The list of
167 significant cell types and their associated medians and FDR-P values are reported in
168 Supplementary Table 5.

169 As we had collected multiple sample types per participant, we were able to test for
170 correlations in immune cell proportions between the upper and lower airway in the same
171 individuals. Due to limited numbers of paired BAL-nasal, and paired BAL-bronchial
172 samples, we could not perform this analysis for these sample types. However, we were able
173 to perform cross-tissue analysis for paired nasal and bronchial samples (n=13), paired nasal
174 and blood samples (n=29) and paired bronchial and blood samples (n=15). This revealed that
175 nasal and bronchial samples were highly correlated within individuals, with positive
176 correlations observed between eosinophils (spearman coefficient (ρ)=0.85, FDR-P=0.002),
177 neutrophils (ρ =0.64, FDR-P=0.03), CD4 T cells (ρ =0.70, FDR-P=0.02), CD8 T cells (ρ =0.69,
178 FDR-P=0.02), monocytes (ρ =0.72, FDR-P=0.02) and cDCs (ρ =0.92, FDR-P=0.0002) in the
179 nasal and bronchial samples (Figure 5C). On the contrary, we observed no statistical
180 correlation in immune cell proportions between blood and nasal samples within individuals,
181 and only NK-T cells were significantly correlated between blood and bronchial samples
182 (ρ =0.72, FDR-P=0.03) (Figure 5C). All correlation coefficients and FDR-P values are
183 reported in Supplementary Table 6.

184 **6. Cross-tissue analysis of cell type proportions in the upper airway lymphoid tissue**

185 Next, we directly compared the composition of immune cells across tonsil, adenoid, and
186 blood compartments. As can be seen in Figure 6A, tonsil and adenoid cell compositions were
187 similar, particularly for NK-T cells, innate lymphoid cells (ILCs), all CD8 T cell subsets, all
188 CD4 T cell subsets and Tregulatory cells. Blood samples showed higher frequencies of innate
189 immune cells, NK/ILCs, as well as naïve CD8- and CD4- T cells, and lower frequencies of
190 TFH cells and the B cell lineage when compared to tonsils and adenoids (Figure 6A,

191 statistical comparison presented in Supplementary Figure 5). Cross-sectional statistical
192 comparison of tonsils vs adenoids showed that plasmablasts, GC B cells, and neutrophils
193 were significantly higher in tonsils compared to adenoids, while pDCs, NK cells, classical
194 memory B cells, and non-switched memory B cells were significantly higher in adenoids
195 compared to tonsils (Figure 6B). The list of significant cell types and their associated
196 medians and FDR-P values are reported in Supplementary Table 7.

197 Finally, we tested for correlations in immune cell proportions between tonsil, adenoid, and
198 blood compartments in paired samples collected from the same individuals (Figure 6C).
199 There were 27 children with paired tonsil and adenoid samples, 25 children with paired tonsil
200 and blood samples, and 30 children with paired adenoid and blood samples. This cross-tissue
201 analysis revealed that tonsil and adenoid samples were highly correlated within individuals,
202 with positive associations observed between 19/25 immune cell populations identified in the
203 lymphoid tissues (Figure 6C). Similarly, blood cells also correlated with cells in the upper
204 airway lymphoid tissue, especially evident for the adenoids where 7/24 populations were
205 positively correlated (Figure 6C). Blood cell proportions positively correlated with tonsil cell
206 proportions for atypical memory B cells, transitional B cells, and CD8 TN within individuals.
207 Blood cell proportions positively correlated with adenoid cell proportions for atypical
208 memory B cells, classical memory B cells, plasma cells, CD8 TCM, CD8 TEM, naïve Tregs
209 and pDCs within individuals. All correlation coefficients and associated FDR-P values are
210 reported in Supplementary Table 8.

211 **DISCUSSION**

212 In recent years, there has been an explosion in the development of single-cell sequencing
213 based tissue atlases, including a global consortium dedicated to profiling the lung ⁸. These
214 studies have provided an unprecedented level of resolution into gene expression of individual
215 cells across many populations. However, due to the extensive laboratory and specialist
216 computational pipelines required for analysis of single-cell sequencing data, these tools are
217 many years away from application in clinical laboratories. Flow cytometry is routinely used
218 in the diagnosis and assessment of human disease globally, and permits multi-dimensional,
219 high-throughput quantification of millions of cells without the requirement for specialist
220 computational analysis ⁹. To our knowledge, we have developed the first flow cytometry-
221 based reference for immune cells in the airways of children. This includes detailed
222 assessment of cell populations in the nose, upper airway lymphoid tissue, as well as the lower
223 airway epithelium and alveolar space; a detailed analysis of surface markers present on each
224 cell population in each tissue; and investigation of cell frequencies across time and space. We
225 also present a reference for immune cells in whole blood samples collected from the same
226 children. The goal of this work was to understand the relationship between airway and
227 systemic immunity from paired paediatric samples, however we also hope it adds valuable
228 data to other efforts investigating immune development in blood, including fresh whole blood
229 ¹⁰, cryopreserved whole blood ¹¹, and cryopreserved PBMC ¹² samples. To facilitate the
230 application and implementation of our tissue references, all protocols, flow cytometry panels,
231 and data are openly available.

232 Our results show tissue-specific maturation of the airway immune system with age. For
233 example, we did not show changes in immune cell proportions throughout childhood in nasal
234 samples, however a marked increase in macrophages and NK-T cells were observed during
235 childhood in bronchial samples. We were fascinated to find strikingly high immune:epithelial
236 cell ratios in nasal and bronchial brushings samples, particularly the high proportions of
237 neutrophils. A recent study that used single-cell sequencing to profile immune cells in nasal
238 swabs from children with SARS-CoV-2 infection as well as non-infected controls reported
239 similar findings. They showed that while immune cells were rarely detected in nasal swabs
240 from healthy adults, samples from healthy children contained high amounts of immune cell
241 subsets with an overall dominance of neutrophils ¹³. Regarding the lymphoid tissues, both
242 tonsil and adenoid samples showed increases in classical memory B cells, CD8 TEM cells
243 and CD4 Thelper cells with age, as well as a decrease in transitional B cells. Adenoid cells,

244 however, appeared more influenced by age, with additional significant associations observed
245 in germinal centre B cells, non-switched memory B cells, NK-T cells and TFH cells. Similar
246 age-related changes in airway lymphoid tissues have been observed previously, particularly
247 related to germinal centre development in tonsils¹⁴. For blood immune cells, we replicate
248 what has been observed in another study focusing on lymphocyte populations from a large
249 number of paediatric whole blood samples where plasmablasts, transitional B cells, and CD4
250 T naïve cells decreased with age and CD4 Thelper cells increased with age¹⁰. We
251 additionally show that whole blood NK-T cells, neutrophils, cDCs, and intermediate
252 monocytes are also associated with age. Collectively, these age-related changes in immune
253 cell composition further highlight the importance of developing age-specific references for
254 the airways and blood of children. This work also highlights that many single-cell sequencing
255 based tissue atlases that primarily consist of samples obtained from adults may not be
256 applicable to children, and we support the efforts of the Pediatric Cell Atlas to include data
257 that samples the complete human lifespan¹⁵.

258 Our intra-individual cross-tissue analysis revealed high correlation in immune cell
259 proportions between tissues, particularly for paired nasal and bronchial samples, paired tonsil
260 and adenoid samples, and paired adenoid and blood samples. These findings suggest that
261 easily accessible nasal samples could be used as a surrogate for assessment of immunity in
262 the lower airway of children. If validated in future studies, this could have important
263 implications for clinical testing, and potentially prevent risks associated with general
264 anaesthesia to sample the lower airway. The remarkable correlation in immune cell
265 composition between the tonsils and adenoids is likely explained by the fact both tissues are
266 part of Waldeyer's ring of pharyngeal lymphoid organs.

267 We acknowledge the limitations of our dataset, in particular the limited number of BAL
268 samples which did not permit age-related or cross-tissue analysis for this sample type. This is
269 due to the difficulties in obtaining these lower airway samples from children, as well as
270 limitations in sample volumes for research testing. However, we were able to obtain samples
271 from a larger number of children for all other sample types (n=17-49), and these numbers are
272 similar to or above that of other immunological studies using paediatric respiratory specimens
273^{13, 16-18}. We also acknowledge that these samples were collected as part of clinically indicated
274 procedures, which means that not all samples can be considered 'healthy'. The main
275 indication in our cohort was OSA, with >80% of samples obtained from children exhibiting
276 or undergoing investigation for this indication. While this may contribute to some variation in

277 tonsil or adenoid immune cell proportions¹⁸, the effect of this underlying condition on results
278 obtained from distal sample types in these children (nasal brushings, bronchial brushings,
279 blood) is unclear. A recent review revealed conflicting evidence of immune cell alterations in
280 adult and paediatric OSA, with some studies reporting an inflammatory effect while others
281 reported normal immune responses in these patients¹⁹. All children in our cohort were
282 clinically well at the time of sample collection and there was limited evidence of wheezing or
283 respiratory infection in the week leading up to sample collection. Parent questionnaires
284 revealed that the majority of children in our cohort had never been prescribed respiratory
285 medications, and of those prescribed, rates of medication use were similar to what is observed
286 in the Australian community for children aged 0-15years²⁰. Likewise, rates of conditions
287 including general atopy, asthma, and eczema, were similar to a recent population-based study
288 of Australian children²¹. As general anaesthesia is required to collect many of the sample
289 types included in our study, creating control respiratory datasets from healthy children in the
290 community is not feasible, especially datasets that include multiple sample types from the
291 same individual, Our reference can be used as control data for clinical samples collected from
292 children with acute (e.g. infectious), rare (e.g. cystic fibrosis, primary ciliary dyskinesia) and
293 chronic (e.g. suppurative lung disease) respiratory conditions.

294 In summary, this study advances our knowledge of airway immunity from infancy through to
295 adolescence and provides an easily adaptable, publicly available control dataset to aid in
296 interpretation of clinical samples obtained from children with respiratory disease.

297 **MATERIALS AND METHODS**

298

299 **Study participants**

300 This study took place at the Royal Children’s Hospital (RCH, Melbourne Australia) and
301 involved analysis of 178 samples from 66 children (Figure 1A, Supplementary Table 1) aged
302 between 1 and 15 years. Samples were collected at the time of clinically indicated procedures
303 (bronchoscopy, tonsillectomy and/or adenoidectomy). Reasons for procedures are detailed in
304 Supplementary Table 1 and medical history from parent questionnaires are summarised in
305 Supplementary Table 2.

306 **Collection and processing of samples**

307 Samples were collected at the time of clinically indicated procedures (bronchoscopy,
308 tonsillectomy and/or adenoidectomy). For palatine tonsils (“tonsils”) and adenotonsils
309 (“adenoids”), tissues were removed by the operating team as per standard operating
310 procedures, suspended in RPMI media supplemented with 2% fetal calf serum (FCS), and
311 transferred on ice to the laboratory immediately upon collection. For nasal brushings, samples
312 were collected by a respiratory physician using a 3mm cytology brush at the time of the
313 procedure, suspended in cold RPMI media supplemented with 2% FCS and transferred on ice
314 to the laboratory immediately upon collection. Bronchial brushings were collected by a
315 respiratory physician using a 2mm cytology brush and suspended in cold RPMI media
316 supplemented with 2% FCS and transferred on ice to the laboratory immediately upon
317 collection. Bronchoscopy and bronchoalveolar lavage (BAL) were performed as previously
318 described where indicated for investigation of stridor²². This study used BAL from aliquots
319 two and three from the right middle lobe. BAL samples were transferred on ice to the
320 laboratory immediately upon collection. Venous blood was collected in EDTA tubes at the
321 time of the procedure and transferred to the laboratory at room temperature immediately upon
322 collection. Multiple sample types were collected from each individual (Figure 1A).

323 Detailed protocols for the collection, processing and flow cytometry analysis of each sample
324 type are openly available at: protocols.io/workspaces/earlyAIR. Briefly, cells were dislodged
325 off nasal and bronchial brushes into media by pipetting for at least 1 minute. Cells were
326 filtered through a 70µM cell strainer into a new 15mL tube and centrifuged at 300xg for 7
327 minutes at 4 degrees. Cells were counted using the LUNA-FL Dual Fluorescence cell counter
328 and washed once more before 300,000 cells were aliquoted for flow cytometry as described

329 below. BAL samples were centrifuged at 300xg for 7 minutes at 4 degrees. The cell-free
330 supernatant was removed and cells were resuspended in 10mL of media. Cells were filtered
331 through a 70µM cell strainer into a new 15mL tube and centrifuged at 300xg for 7 minutes at
332 4 degrees. Cells were counted using the LUNA-FL cell counter and washed once more before
333 300,000 cells were aliquoted for flow cytometry as described below. Tonsil and adenoid
334 samples were processed in glass culture plates with 10mL of media. First, visible blood clots,
335 fat and connective tissue were removed using forceps and scissors. Next, the tissues were
336 minced into a fine paste using scissors in a fresh glass plate with fresh media and filtered
337 through a 100µm cell strainer into a 50mL tube. Cells were centrifuged at 400xg for 5
338 minutes at room temperature and resuspended in 8mL of fresh media prior to layering onto
339 Ficoll plaque plus as per the manufacturer's instructions. Cells were centrifuged at 400xg for
340 30 minutes at room temperature with a slow acceleration and no brake. Cells at the interface
341 between media and the Ficoll solution were collected into a new 15mL tube and washed with
342 media before counting using the LUNA-FL cell counter. Due to the large number of cells
343 collected, cells were diluted between 1:10-1:100 prior to counting. Finally, 500,000 cells
344 were aliquoted for flow cytometry as described below.

345 **Flow cytometry of nasal brushings, bronchial brushings, and BAL samples**

346 Nasal, bronchial and BAL cells were resuspended in PBS for viability staining using near
347 infra-red viability dye according to manufacturers' instructions. The viability dye reaction
348 was stopped by the addition of FACS buffer (2% heat-inactivated FCS in PBS) and cells were
349 centrifuged at 400xg for 5 mins 4°C. Cells were resuspended in 25µL human FC-block
350 (diluted 1:10) for 5 minutes at room temperature. The flow cytometry staining panel
351 described in Supplementary Table 3 (made up at 2X concentration) was added 1:1 with the
352 cells and incubated for 30 minutes on ice. Following staining, cells were washed with 1mL
353 FACS buffer and centrifuged at 400xg for 5 minutes 4°C. Cells were resuspended in 150µL
354 FACS buffer for acquisition using the Cytex 5L Aurora. The gating strategy used to define
355 cell types obtained with this panel is depicted in Supplementary Figure 1.

356 **Flow cytometry of tonsils, adenoids, and whole blood samples**

357 Tonsil, adenoid and lysed whole blood cells were resuspended in PBS for viability staining
358 using near UV-blue viability dye according to manufacturers' instructions. The viability dye
359 reaction was stopped by the addition of FACS buffer and cells were centrifuged at 400xg for
360 5 mins 4°C. Cells were resuspended in 40µL human FC-block (diluted 1:10) for 5 minutes at

361 room temperature, following which 10µL of Brilliant Stain Buffer Plus was added. The
362 chemokine panel described in Supplementary Table 4A (made up at 3X concentration) was
363 added at 25µL per sample and cells incubated for 10 minutes at room temperature in the dark.
364 The panel described in Supplementary Table 4B (made up at 3X concentration) was added at
365 50µL per sample and cells incubated for 30 minutes at room temperature in the dark.
366 Following staining, cells were washed with 1mL FACS buffer and centrifuged at 400xg for 5
367 minutes 4°C. Cells were resuspended in 150µL FACS buffer for acquisition using the Cytex
368 5L Aurora. The gating strategy used to define cell types obtained with this panel is depicted
369 in Supplementary Figure 2. The panel described in Supplementary Table 4 is a modified
370 version of the published OMIP-069²³.

371 **Data analysis**

372 Gating of flow cytometry data was performed in FlowJo version 10.9.0. As samples were
373 acquired fresh on the day of collection over multiple batches, all data was normalised using
374 the cyCombine plugin²⁴. For each tissue type, cell populations were annotated based on
375 expression of known lineage markers included in each panel (see gating strategies for each
376 tissue in the Supplement). Cell population frequencies were expressed as a proportion of live,
377 single cells or as a proportion of live, single, CD45⁺ cells when referring to analysis of
378 immune cell types only. For age-specific immune cell reference ranges (Tables 1-6), median
379 frequencies (% of live, single, CD45⁺ cells) were calculated for each cell type within each
380 age group (0-2years, 3-5 years, 6-10 years, 11-15 years) and the ranges also reported. For
381 unsupervised analyses, a single concatenated file was created for each tissue type, containing
382 10,000 downsampled cells from each participant. These concatenated files were used for
383 Uniform Manifold Approximation and Projection (UMAP) analysis (using the default settings
384 of the UMAP plugin for FlowJo) and to calculate the median fluorescence intensity (MFI) of
385 each lineage marker for each cell type in each tissue. Hierarchical clustering analysis and
386 heatmap visualisation of the MFI data was done using the pheatmap package in R Studio
387 version 4.3.0. For cross-sectional statistical analysis, cell proportions were compared using
388 Mann Whitney U-tests. All p-values were corrected for false discovery rate using the
389 Benjamini and Hochberg approach²⁵. An FDR corrected p<0.05 and a fold change of >1.5
390 was required to reach statistical significance. Age and intra-individual correlations were
391 determined using two-tailed spearman tests. Spearman P-values were corrected for false
392 discovery rate using the Benjamini and Hochberg approach. An FDR corrected p<0.05 was
393 required to reach statistical significance.

394 **Ethics statement**

395 The studies involving human participants were reviewed and approved by Royal Children’s
396 Hospital Human Research Ethics Committee (HREC #25054 and # 88144). Written informed
397 consent to participate in the studies was provided by the participants’ legal guardian/next of
398 kin.

399 References

- 400 1. Stocks, J., Hislop, A. & Sonnappa, S. Early lung development: lifelong effect on
401 respiratory health and disease. *Lancet Respir Med* **1**, 728-742 (2013).
- 402 2. Schnabl, K., Chan, M.K., Gong, Y. & Adeli, K. Closing the gaps in paediatric
403 reference intervals: the CALIPER initiative. *Clin Biochem Rev* **29**, 89-96 (2008).
- 404 3. Tosato, F. *et al.* Lymphocytes subsets reference values in childhood. *Cytometry. Part*
405 *A : the journal of the International Society for Analytical Cytology* **87**, 81-85 (2015).
- 406 4. Lyle, A.N. *et al.* Current State of Pediatric Reference Intervals and the Importance of
407 Correctly Describing the Biochemistry of Child Development: A Review. *Jama*
408 *Pediatr* **176**, 699-714 (2022).
- 409 5. Zimmermann, P. & Curtis, N. Why is COVID-19 less severe in children? A review of
410 the proposed mechanisms underlying the age-related difference in severity of SARS-
411 CoV-2 infections. *archdischild-2020-320338* (2020).
- 412 6. Coultas, J.A., Smyth, R. & Openshaw, P.J. Respiratory syncytial virus (RSV): a
413 scourge from infancy to old age. *Thorax* **74**, 986-993 (2019).
- 414 7. Morris, I. *et al.* Which intravenous bronchodilators are being administered to children
415 presenting with acute severe wheeze in the UK and Ireland? *Thorax* **70**, 88-91 (2015).
- 416 8. Sikkema, L. *et al.* An integrated cell atlas of the lung in health and disease. *Nature*
417 *Medicine* **29**, 1563-1577 (2023).
- 418 9. Virgo, P.F. & Gibbs, G.J. Flow cytometry in clinical pathology. *Annals of Clinical*
419 *Biochemistry* **49**, 17-28 (2012).
- 420 10. Ding, Y. *et al.* Reference values for peripheral blood lymphocyte subsets of healthy
421 children in China. *J Allergy Clin Immunol* **142**, 970-973.e978 (2018).
- 422 11. Olin, A. *et al.* Stereotypic Immune System Development in Newborn Children. *Cell*
423 **174**, 1277-1292.e1214 (2018).
- 424 12. Jalali, S. *et al.* A high-dimensional cytometry atlas of peripheral blood over the human
425 life span. *Immunol Cell Biol* **100**, 805-821 (2022).
- 426 13. Loske, J. *et al.* Pre-activated antiviral innate immunity in the upper airways controls
427 early SARS-CoV-2 infection in children. *Nat Biotechnol* **40**, 319-324 (2022).
- 428 14. Massoni-Badosa, R. *et al.* An atlas of cells in the human tonsil. *Immunity* **57**, 379-
429 399.e318 (2024).
- 430 15. Taylor, D.M. *et al.* The Pediatric Cell Atlas: Defining the Growth Phase of Human
431 Development at Single-Cell Resolution. *Developmental Cell* **49**, 10-29 (2019).
- 432 16. King, H.W. *et al.* Single-cell analysis of human B cell maturation predicts how
433 antibody class switching shapes selection dynamics. *Science immunology* **6** (2021).
- 434 17. Neeland, M.R. *et al.* Pulmonary immune profiling reveals common inflammatory
435 endotypes of childhood wheeze and suppurative lung disease. *Mucosal Immunol*
436 (2024).
- 437 18. Carrasco, A. *et al.* The Tonsil Lymphocyte Landscape in Pediatric Tonsil Hyperplasia
438 and Obstructive Sleep Apnea. *Frontiers in immunology* **12**, 674080 (2021).
- 439 19. Ludwig, K., Huppertz, T., Radsak, M. & Gouveris, H. Cellular Immune Dysfunction
440 in Obstructive Sleep Apnea. *Front Surg* **9**, 890377 (2022).
- 441 20. Welfare, A.I.o.H.a. Asthma. (2023).
- 442 21. Peters, R.L. *et al.* The Prevalence of IgE-Mediated Food Allergy and Other Allergic
443 Diseases in the First 10 Years: The Population-Based, Longitudinal HealthNuts Study.
444 *The journal of allergy and clinical immunology. In practice* (2024).
- 445 22. Sly, P.D. *et al.* Risk factors for bronchiectasis in children with cystic fibrosis. *N Engl J*
446 *Med* **368**, 1963-1970 (2013).

- 447 23. Park, L.M., Lannigan, J. & Jaimes, M.C. OMIP-069: Forty-Color Full Spectrum Flow
448 Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets in Human
449 Peripheral Blood. *Cytometry A* **97**, 1044-1051 (2020).
450 24. Pedersen, C.B. *et al.* cyCombine allows for robust integration of single-cell cytometry
451 datasets within and across technologies. *Nat Commun* **13**, 1698 (2022).
452 25. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate - a Practical and
453 Powerful Approach to Multiple Testing. *J R Stat Soc B* **57**, 289-300 (1995).

454

455

456 **ACKNOWLEDGEMENTS**

457 This work was funded by a Chan Zuckerberg Initiative Single-Cell Biology Grant (2021-
458 237883). We thank the children and parents who participated in our studies, without whom
459 this work would not exist.

460

461

462 **FIGURE LEGENDS**

463 **Figure 1.** Overview of the experimental design and cellular landscape of each tissue. (A) 66
464 children aged between 1 and 15 years were recruited into the earlyAIR study. There were 10
465 infants (age 0-2 years), 21 preschoolers (age 3-5 years), 22 children (6-10 years), and 13
466 adolescents (11-15 years). From these 66 children, 178 samples were collected across six
467 tissue types: nasal brushings (n=37), bronchial brushings (n=17), bronchoalveolar lavage
468 (BAL) (n=8), adenoids (n=36), tonsils (n=31), and whole blood (n=49). (B) Each sample type
469 was processed into a single-cell suspension and analysed by spectral flow cytometry. Nasal
470 brushing, bronchial brushing, and BAL samples were analysed using a 17-plex lung panel.
471 Tonsil, adenoid, and whole blood samples were analysed using a 31-plex tonsil-adenoid-
472 blood panel. (C) Uniform Manifold Approximation and Projection (UMAP) plots showing
473 the cellular landscape of nasal, bronchial and alveolar cells identified using the lung panel.
474 (D) UMAP plots showing the cellular landscape of tonsil, adenoid, and blood cells identified
475 using the tonsil-adenoid-blood panel.

476 **Figure 2.** Marker expression and proportion of cell populations identified in paediatric nasal,
477 bronchial, and alveolar samples. (A) Heatmap depicting hierarchical clustering analysis of the
478 normalised median fluorescence intensity (MFI) of 16 lineage markers on cell types
479 identified in nasal brushings samples. (B) Heatmap depicting hierarchical clustering analysis
480 of the normalised MFI of 16 lineage markers on cell types identified in bronchial brushings
481 samples. (C) Heatmap depicting hierarchical clustering analysis of the normalised MFI of 16
482 lineage markers on cell types identified in BAL samples. (D) Proportion of immune and
483 epithelial lineages in nasal brushings samples. (E) Proportion of immune and epithelial lineages
484 in bronchial brushings samples. (F) Proportion of immune and epithelial lineages in BAL
485 samples. (G) Box plots depicting individual cell proportions for 10 broad immune cell types
486 identified in nasal brushings samples (H) Box plots depicting individual cell proportions for
487 10 broad immune cell types identified in bronchial brushings samples. (I) Box plots depicting
488 individual cell proportions for 10 broad immune cell types identified in BAL samples. P-
489 values determined by Mann-Whitney U-test where $p < 0.05$ was considered significant.

490 **Figure 3.** Marker expression and proportion of cell populations identified in paediatric tonsil,
491 adenoid, and whole blood samples. (A) Heatmap depicting hierarchical clustering analysis of
492 the normalised median fluorescence intensity (MFI) of 22 lineage markers on cell types
493 identified in tonsils. (B) Heatmap depicting hierarchical clustering analysis of the normalised
494 MFI of 22 lineage markers on cell types identified in adenoids. (C) Heatmap depicting
495 hierarchical clustering analysis of the normalised MFI of 22 lineage markers on cell types
496 identified in blood. (D) Box plots depicting individual cell proportions for 25 immune cell
497 types identified in tonsils. (E) Box plots depicting individual cell proportions for 25 immune
498 cell types identified in adenoids. (F) Box plots depicting individual cell proportions for 30
499 immune cell types identified in whole blood samples.

500 **Figure 4.** Immune cell type proportions in bronchial, tonsil, adenoid and blood samples are
501 associated with age. (A) Spearman coefficient (ρ) and FDR-corrected p-values for nasal
502 immune cell types significantly associated with age: CD66b^{low}CD16⁺ neutrophils,
503 macrophages, and NK-T cells. (B) Spearman ρ and FDR-corrected p-values for bronchial
504 immune cell types significantly associated with age: transitional B cells, classical memory B
505 cells, CD8 T_{EM}, and CD4 Thelper cells. (C) Spearman ρ and FDR-corrected p-values for
506 adenoid immune cell types significantly associated with age: germinal centre B cells,
507 transitional B cells, non-switched memory B cells, classical memory B cells, CD4 Thelper
508 cells, NK-T cells, CD8 T_{EM}, and TFH cells. (D) Spearman ρ and FDR-corrected p-values for
509 blood immune cell types significantly associated with age: plasmablasts, transitional B cells,

510 NK-T cells, CD4 TN cells, CD4 Thelper cells, neutrophils, intermediate monocytes, and
511 cDCs. Note there were no significant correlations with age for cell types in nasal or alveolar
512 samples. Correlation p-values were determined by two-tailed spearman test and corrected for
513 false discovery rate using the Benjamini Hochberg approach. FDR-P<0.05 was considered
514 significant.

515 **Figure 5.** Cross-tissue analysis of cell type proportion in lung and blood compartments
516 reveals high correlation between upper and lower airway brushings but limited correlation
517 between the lung and blood in children. **(A)** Median immune cell type proportion in nasal,
518 bronchial, and alveolar samples for granulocytes (left panel), myeloid cells (centre panel) and
519 lymphocytes (right panel). **(B)** Volcano plots depicting cross-sectional statistical analysis of
520 cell types in nasal_vs_bronchial samples (left panel), nasal_vs_alveolar samples (centre
521 panel), and bronchial_vs_alveolar samples (right panel). **(C)** Ballon plot depicting intra-
522 individual correlations of cell type proportions for participants who had nasal, bronchial, and
523 blood samples analysed. * Depicts significant correlation. NA: Not Applicable, as
524 macrophages are not present in blood. Cross-sectional p-values (part B) were determined by
525 Mann-Whitney U-test and corrected for false discovery rate using the Benjamini Hochberg
526 approach. FDR p<0.05 and fold change >1.5 was considered significant. Intra-individual
527 correlation p-values (part C) were determined by two-tailed spearman test and corrected for
528 false discovery rate using the Benjamini Hochberg approach. FDR-P<0.05 was considered
529 significant.

530 **Figure 6.** Cross-tissue analysis of cell type proportion in tonsil, adenoid and blood
531 compartments reveals sample-type specific immune cell profiles and an intra-individual
532 tonsil-adenoid-blood immune cell axis in children. **(A)** Median immune cell type proportion
533 in tonsil, adenoid, and blood samples for granulocytes and myeloid cells (first panel), innate
534 lymphocytes (second panel), CD8 T cell populations (third panel), CD4 T cell populations
535 (fourth panel) and B cell populations (fifth panel). **(B)** Volcano plot depicting cross-sectional
536 statistical analysis of cell types in tonsil_vs_adenoid samples. **(C)** Ballon plot depicting intra-
537 individual correlations of cell type proportions for participants who had tonsil, adenoid, and
538 blood samples analysed. * Depicts significant correlation. NA: Not Applicable, as GC B cells
539 are not present in blood. Cross-sectional p-values (part B) were determined by Mann-
540 Whitney U-test and corrected for false discovery rate using the Benjamini Hochberg
541 approach. FDR p<0.05 and fold change >1.5 was considered significant. Intra-individual
542 correlation p-values (part C) were determined by two-tailed spearman test and corrected for
543 false discovery rate using the Benjamini Hochberg approach. FDR-P<0.05 was considered
544 significant.

545 **Table 1.** Immune cell subtype frequency in nasal brushings samples from children aged 0-15
 546 years.

NASAL IMMUNE CELLS	0-15 years (n=37)	0-2 years (n=5)	3-5 years (n=16)	6-10 years (n=12)	11-15 years (n=4)
Total granulocytes %CD45 ⁺ cells Median (range)	31.72 (2.92-88.20)	29.09 (23.42-79.66)	46.03 (6.93-79.63)	20.40 (2.92-88.20)	51.67 (42.28-64.37)
Eosinophils %CD45 ⁺ cells Median (range)	0.22 (0.01-31.62)	0.34 (0.16-0.50)	0.16 (0.02-2.16)	0.61 (0.01-31.62)	0.63 (0.02-21.92)
Neutrophils %CD45 ⁺ cells Median (range)	28.17 (2.51-78.26)	28.17 (20.55-71.76)	42.84 (6.83-78.26)	14.35 (2.51-60.89)	43.52 (39.82-52.74)
Macrophages %CD45 ⁺ cells Median (range)	0.99 (0.27-13.63)	1.16 (0.30-8.37)	0.78 (0.27-9.69)	1.14 (0.46-13.63)	1.16 (0.79-3.29)
NK cells %CD45 ⁺ cells Median (range)	0.64 (0.12-3.96)	1.03 (0.48-2.9)	0.74 (0.12-3.96)	0.42 (0.15-3.39)	0.59 (0.31-0.60)
NK-T cells %CD45 ⁺ cells Median (range)	0.16 (0.01-2.23)	0.27 (0.06-2.23)	0.10 (0.04-1.02)	0.13 (0.01-0.62)	0.18 (0.02-0.23)
CD8 T cells %CD45 ⁺ cells Median (range)	20.71 (1.36-43.14)	20.25 (6.48-31.47)	19.09 (1.36-43.14)	22.12 (1.71-31.69)	24.29 (13.34-35.89)
CD4 T cells %CD45 ⁺ cells Median (range)	5.91 (0.23-17.72)	8.94 (0.23-17.72)	5.19 (1.54-14.64)	9.33 (1.91-16.90)	4.32 (3.46-7.00)
B cells %CD45 ⁺ cells Median (range)	3.92 (0.26-35.02)	2.82 (0.26-7.07)	5.51 (2.57-35.02)	3.73 (0.54-33.71)	1.53 (0.26-2.64)
Monocytes %CD45 ⁺ cells Median (range)	0.50 (0.08-14.72)	1.20 (0.08-14.06)	0.48 (0.14-3.08)	0.46 (0.15-14.72)	0.33 (0.16-2.72)
cDCs %CD45 ⁺ cells Median (range)	0.47 (0.01-4.55)	1.57 (0.01-4.55)	0.43 (0.01-2.66)	0.36 (0.23-2.07)	0.63 (0.43-1.14)

547 **Table 2.** Immune cell subtype frequency in bronchial brushings samples from children aged
 548 0-15 years.

549

BRONCHIAL IMMUNE CELLS	0-15 years (n=17)	0-5 years (n=8)	6-10 years (n=5)	11-15 years (n=4)
Total granulocytes %CD45 ⁺ cells Median (range)	40.84 (1.85-89.57)	58.86 (5.04-89.57)	18.34 (1.85-56.76)	33.53 (15.00-47.55)
Eosinophils %CD45 ⁺ cells Median (range)	0.41 (0.01-4.41)	0.23 (0.02-1.52)	1.66 (0.12-4.04)	2.34 (0.01-4.41)
Neutrophils %CD45 ⁺ cells Median (range)	30.75 (1.58-85.04)	56.10 (4.6-85.04)	15.91 (1.58-52.41)	20.41 (9.88-37.80)
Macrophages %CD45 ⁺ cells Median (range)	3.46 (0.68-11.56)	1.47 (0.68-3.71)	3.53 (3.09-10.74)	9.03 (3.62-11.56)
NK cells %CD45 ⁺ cells Median (range)	1.46 (0.26-5.88)	1.24 (0.31-5.88)	0.98 (0.26-1.83)	2.74 (0.61-4.44)
NK-T cells %CD45 ⁺ cells Median (range)	0.98 (0.07-6.56)	0.33 (0.07-2.05)	1.70 (0.16-2.65)	2.60 (0.78-6.56)
CD8 T cells %CD45 ⁺ cells Median (range)	13.78 (0.86-33.92)	7.89 (1.85-21.82)	13.78 (0.86-33.92)	22.56 (8.43-27.76)
CD4 T cells %CD45 ⁺ cells Median (range)	3.35 (0.06-19.24)	3.77 (0.11-19.24)	4.23 (1.58-10.50)	6.49 (0.06-18.61)
B cells %CD45 ⁺ cells Median (range)	2.10 (0.29-12.61)	2.54 (0.5-5.35)	1.86 (0.29-12.26)	1.87 (0.67-12.61)
Monocytes %CD45 ⁺ cells Median (range)	1.27 (0.01-15.58)	1.53 (0.08-15.58)	1.59 (0.31-5.95)	0.73 (0.01-1.39)
cDCs %CD45 ⁺ cells Median (range)	0.70 (0.01-2.11)	0.73 (0.01-2.11)	0.70 (0.04-1.59)	0.87 (0.01-1.52)

550 **Table 3.** Immune cell subtype frequency in bronchoalveolar lavage (BAL) samples from
 551 children aged 0-15 years.

ALVEOLAR IMMUNE CELLS	0-15 years (n=8)	0-5 years (n=5)	6-10 years (n=3)
Total granulocytes %CD45 ⁺ cells Median (range)	1.88 (0.49-8.48)	1.59 (0.49-8.49)	2.16 (0.53-3.51)
Eosinophils %CD45 ⁺ cells Median (range)	0.06 (0.003-0.20)	0.10 (0.01-0.20)	0.03 (0.02-0.10)
Neutrophils %CD45 ⁺ cells Median (range)	1.82 (0.49-8.33)	1.5 (0.49-8.33)	2.13 (0.50-3.40)
Macrophages %CD45 ⁺ cells Median (range)	80.05 (58.77-87.01)	78.5 (58.77-83.60)	84.37 (73.82-87.01)
NK cells %CD45 ⁺ cells Median (range)	0.39 (0.10-0.90)	0.21 (0.10-0.90)	0.42 (0.35-0.43)
NK-T cells %CD45 ⁺ cells Median (range)	0.19 (0.02-0.63)	0.13 (0.02-0.23)	0.54 (0.32-0.63)
CD8 T cells %CD45 ⁺ cells Median (range)	3.87 (0.35-10.96)	4.11 (0.35-10.96)	3.62 (3.5-6.54)
CD4 T cells %CD45 ⁺ cells Median (range)	3.42 (0.01-8.78)	3.49 (0.01-6.45)	2.64 (2.38-8.78)
B cells %CD45 ⁺ cells Median (range)	0.97 (0.16-5.09)	1.25 (0.37-5.09)	0.69 (0.16-1.55)
Monocytes %CD45 ⁺ cells Median (range)	0.46 (0.15-2.41)	0.99 (0.15-2.41)	0.20 (0.19-0.38)
cDCs %CD45 ⁺ cells Median (range)	0.65 (0.10-1.61)	0.94 (0.10-1.61)	0.52 (0.37-0.78)

552

553

554 **Table 4.** Immune cell subtype frequency in tonsils from children aged 0-15 years.

TONSIL IMMUNE CELLS	0-15 years (n=31)	0-2 years (n=5)	3-5 years (n=13)	6-10 years (n=9)	11-15 years (n=4)
Neutrophils %CD45 ⁺ cells Median (range)	0.59 (0.05-2.36)	0.17 (0.06-1.29)	0.70 (0.05-1.52)	0.49 (0.19-1.18)	2.03 (1.34-2.36)
Plasma blasts %CD45 ⁺ cells Median (range)	1.38 (0.41-3.54)	1.53 (1.20-1.95)	1.33 (0.54-2.91)	1.60 (0.41-3.54)	1.32 (0.94-1.81)
GC B cells %CD45 ⁺ cells Median (range)	18.84 (7.16-42.73)	22.69 (7.16-42.73)	18.47 (9.64-30.00)	19.01 (9.31-27.40)	9.59 (7.25-24.30)
Atypical memory B cells %CD45 ⁺ cells Median (range)	3.62 (1.44-8.64)	2.19 (1.78-2.98)	4.42 (2.47-7.01)	3.62 (1.82-4.50)	2.79 (1.44-8..64)
Classical memory B cells %CD45 ⁺ cells Median (range)	1.63 (0.45-3.72)	0.53 (0.45-1.60)	1.80 (0.79-2.59)	1.47 (0.77-3.72)	2.77 (1.56-3.39)
Naïve B cells %CD45 ⁺ cells Median (range)	16.45 (4.44-36.15)	14.39 (9.73-29.40)	15.07 (9.93-19.94)	16.53 (4.44-29.87)	18.44 (17.06-36.15)
Non-switched memory B cells %CD45 ⁺ cells Median (range)	1.69 (0.61-7.88)	1.29 (0.74-1.92)	1.77 (0.87-3.99)	1.69 (0.61-7.88)	2.51 (1.30-2.77)
Plasma cells %CD45 ⁺ cells Median (range)	0.40 (0.02-1.96)	0.16 (0.03-1.31)	0.40 (0.04-1.96)	0.45 (0.15-0.64)	0.10 (0.02-0.70)
Transitional B cells %CD45 ⁺ cells Median (range)	10.27 (4.06-17.21)	14.81 (6.50-17.21)	11.33 (7.36-14.24)	8.76 (4.06-13.25)	5.90 (5.04-10.02)
NK cells %CD45 ⁺ cells Median (range)	0.37 (0.08-1.09)	0.37 (0.22-0.80)	0.37 (0.1-1.09)	0.37 (0.08-0.59)	0.37 (0.24-0.50)
NK-T cells %CD45 ⁺ cells Median (range)	0.09 (0.02-0.21)	0.07 (0.02-0.21)	0.09 (0.04-0.20)	0.11 (0.03-0.18)	0.05 (0.04-0.12)
CD8 TCM %CD45 ⁺ cells Median (range)	1.35 (0.2-4.34)	0.41 (0.20-1.38)	1.11 (0.33-4.34)	1.35 (0.46-3.11)	2.38 (1.94-2.81)
CD8 TN %CD45 ⁺ cells Median (range)	2.79 (0.94-9.54)	2.83 (1.6-9.54)	3.21 (1.51-7.71)	2.97 (1.43-8.29)	1.73 (0.94-2.79)
CD8 TEMRA %CD45 ⁺ cells Median (range)	0.23 (0.12-3.04)	0.22 (0.17-0.38)	0.26 (0.14-0.93)	0.20 (0.36-2.17)	0.19 (0.12-0.41)
CD8 TEM %CD45 ⁺ cells Median (range)	0.52 (0.13-3.01)	0.23 (0.14-0.33)	0.64 (0.13-2.13)	0.53 (0.36-2.17)	1.66 (0.52-3.01)
Activated Tregs %CD45 ⁺ cells Median (range)	0.55 (0.19-1.47)	0.41 (0.19-1.25)	0.54 (0.20-1.47)	0.57 (0.32-0.95)	0.35 (0.31-0.57)

Naive Tregs %CD45 ⁺ cells Median (range)	2.46 (1.13-5.75)	2.76 (1.95-3.10)	2.46 (1.56-5.75)	2.14 (1.43-4.78)	3.01 (1.13-3.62)
TFH cells %CD45 ⁺ cells Median (range)	8.57 (4.59-17.84)	8.49 (6.88-12.10)	8.87 (4.66-11.77)	8.56 (4.63-12.12)	7.20 (4.59-17.84)
CD4 Thelper cells %CD45 ⁺ cells Median (range)	9.19 (3.93-19.32)	7.60 (3.93-8.83)	8.78 (7.16-14.70)	12.10 (7.25-15.06)	13.75 (11.69-19.32)
CD4 TN %CD45 ⁺ cells Median (range)	6.07 (1.61-13.14)	5.65 (3.32-12.31)	6.07 (2.60-10.50)	6.65 (3.34-13.14)	4.35 (1.61-6.59)
CD4 TEMRA %CD45 ⁺ cells Median (range)	0.39 (0.11-2.15)	0.32 (0.21-0.89)	0.44 (0.17-1.59)	0.35 (0.19-2.15)	0.79 (0.11-1.28)
Monocytes %CD45 ⁺ cells Median (range)	0.40 (0.13-1.13)	0.22 (0.13-0.63)	0.47 (0.26-1.13)	0.28 (0.20-0.60)	0.41 (0.28-0.51)
cDCs %CD45 ⁺ cells Median (range)	0.17 (0.04-0.41)	0.16 (0.12-0.22)	0.16 (0.10-0.35)	0.18 (0.04-0.41)	0.17 (0.12-0.39)
pDCs %CD45 ⁺ cells Median (range)	0.32 (0.04-0.89)	0.26 (0.10-0.35)	0.35 (0.19-0.89)	0.28 (0.04-0.54)	0.15 (0.09-0.30)
ILCs %CD45 ⁺ cells Median (range)	0.32 (0.05-0.96)	0.39 (0.10-0.48)	0.48 (0.08-0.96)	0.31 (0.05-0.81)	0.45 (0.27-0.60)

555

556 **Table 5.** Immune cell subtype frequency in adenoids from children aged 0-15 years.

ADENOID IMMUNE CELLS	0-15 years (n=36)	0-2 years (n=4)	3-5 years (n=14)	6-10 years (n=10)	11-15 years (n=8)
Neutrophils %CD45 ⁺ cells Median (range)	0.27 (0.07-3.47)	0.48 (0.21-0.88)	0.29 (0.11-2.83)	0.26 (0.08-0.40)	0.11 (0.07-3.47)
Plasma blasts %CD45 ⁺ cells Median (range)	0.89 (0.31-1.66)	0.83 (0.55-1.30)	1.02 (0.44-1.52)	0.68 (0.31-1.46)	0.90 (0.33-1.66)
GC B cells %CD45 ⁺ cells Median (range)	10.38 (1.76-32.58)	11.33 (8.88-16.06)	14.27 (9.15-32.58)	9.41 (4.31-21.51)	6.49 (1.76-19.93)
Atypical memory B cells %CD45 ⁺ cells Median (range)	3.85 (1.08-9.17)	2.27 (1.73-4.15)	4.59 (2.77-7.08)	3.51 (2.46-6.92)	3.87 (1.08-9.17)
Classical memory B cells %CD45 ⁺ cells Median (range)	2.80 (0.66-8.91)	0.98 (0.66-1.32)	2.88 (1.37-5.88)	3.25 (1.82-7.87)	3.14 (1.74-8.91)
Naïve B cells %CD45 ⁺ cells Median (range)	18.63 (8.30-43.75)	22.71 (11.05-27.67)	17.48 (11.78-36.03)	17.32 (8.30-26.74)	17.89 (11.17-43.75)
Non-switched memory B cells %CD45 ⁺ cells Median (range)	2.72 (0.89-6.63)	1.51 (0.89-2.17)	2.23 (1.37-2.86)	3.94 (1.14-6.63)	4.29 (2.53-5.64)
Plasma cells %CD45 ⁺ cells Median (range)	0.20 (0.03-0.77)	0.14 (0.12-0.25)	0.25 (0.03-0.77)	0.16 (0.04-0.63)	0.20 (0.10-0.57)
Transitional B cells %CD45 ⁺ cells Median (range)	9.48 (3.25-24.75)	14.51 (11.22-24.75)	10.92 (3.25-12.71)	8.06 (5.08-13.53)	6.28 (3.52-16.21)
NK cells %CD45 ⁺ cells Median (range)	0.63 (0.25-1.58)	0.57 (0.42-1.58)	0.77 (0.38-1.26)	0.63 (0.25-1.34)	0.64 (0.35-1.24)
NK-T cells %CD45 ⁺ cells Median (range)	0.09 (0.02-0.52)	0.06 (0.03-0.07)	0.08 (0.02-0.52)	0.11 (0.05-0.19)	0.14 (0.08-0.23)
CD8 TCM %CD45 ⁺ cells Median (range)	0.92 (0.22-3.38)	0.46 (0.31-0.60)	0.92 (0.23-3.10)	1.14 (0.22-3.14)	1.90 (0.50-3.38)
CD8 TN %CD45 ⁺ cells Median (range)	3.37 (0.62-9.69)	5.19 (3.23-8.21)	2.65 (1.75-7.42)	3.32 (1.53-5.90)	3.75 (0.62-9.69)
CD8 TEMRA %CD45 ⁺ cells Median (range)	0.36 (0.11-2.34)	0.47 (0.2-1.12)	0.33 (0.14-0.79)	0.48 (0.20-1.57)	0.20 (0.11-2.34)
CD8 TEM %CD45 ⁺ cells Median (range)	0.83 (0.17-3.13)	0.38 (0.17-0.84)	0.58 (0.27-1.62)	0.92 (0.39-2.88)	1.14 (0.65-3.13)
Activated Tregs %CD45 ⁺ cells Median (range)	0.56 (0.13-1.74)	0.50 (0.27-0.71)	0.49 (0.20-1.13)	0.62 (0.22-1.74)	0.57 (0.13-1.10)

Naive Tregs %CD45 ⁺ cells Median (range)	2.62 (0.91-7.12)	2.24 (1.31-3.11)	2.73 (1.37-5.33)	3.21 (1.31-7.12)	2.60 (0.91-3.45)
TFH cells %CD45 ⁺ cells Median (range)	9.84 (0.50-17.32)	10.95 (8.32-17.32)	10.74 (4.59-14.71)	9.80 (4.64-13.24)	7.34 (0.50-14.33)
CD4 Thelper cells %CD45 ⁺ cells Median (range)	11.90 (1.90-26.26)	6.51 (4.96-9.12)	8.81 (1.90-13.39)	15.18 (7.94-19.69)	16.78 (6.37-26.26)
CD4 TN %CD45 ⁺ cells Median (range)	5.58 (0.86-16.73)	6.83 (5.06-12.27)	4.69 (3.19-8.66)	6.41 (3.66-9.59)	5.57 (0.86-16.73)
CD4 TEMRA %CD45 ⁺ cells Median (range)	0.46 (0.07-1.20)	0.48 (0.23-0.75)	0.51 (0.23-1.06)	0.44 (0.21-1.20)	0.56 (0.07-0.94)
Monocytes %CD45 ⁺ cells Median (range)	0.36 (0.14-1.08)	0.45 (0.21-0.58)	0.46 (0.21-0.86)	0.34 (0.16-1.08)	0.34 (0.14-0.99)
cDCs %CD45 ⁺ cells Median (range)	0.23 (0.09-0.87)	0.19 (0.17-0.25)	0.21 (0.09-0.87)	0.26 (0.12-0.58)	0.24 (0.14-0.50)
pDCs %CD45 ⁺ cells Median (range)	0.83 (0.13-2.98)	0.51 (0.42-1.59)	0.98 (0.29-2.07)	0.68 (0.35-1.64)	1.04 (0.13-2.98)
ILCs %CD45 ⁺ cells Median (range)	0.34 (0.01-1.24)	0.32 (0.26-0.38)	0.33 (0.10-1.24)	0.44 (0.07-0.64)	0.33 (0.01-0.85)

557

558 **Table 6.** Immune cell subtype frequency in whole blood samples from children aged 0-15
559 years.

WHOLE BLOOD IMMUNE CELLS	0-15 years (n=49)	0-2 years (n=6)	3-5 years (n=17)	6-10 years (n=15)	11-15 years (n=11)
Eosinophils %CD45 ⁺ cells Median (range)	0.83 (0.04-11.98)	0.79 (0.29-2.28)	0.60 (0.04-6.55)	1.53 (0.17-11.98)	1.52 (0.13-5.95)
Neutrophils %CD45 ⁺ cells Median (range)	27.50 (9.53-77.72)	25.52 (13.34-75.76)	21.80 (9.53-34.50)	30.68 (14.75-77.72)	38.39 (26.66-54.78)
Plasma blasts %CD45 ⁺ cells Median (range)	0.14 (0.01-0.68)	0.23 (0.04-0.58)	0.18 (0.09-0.68)	0.07 (0.01-0.47)	0.06 (0.02-0.37)
Atypical memory B cells %CD45 ⁺ cells Median (range)	0.56 (0.17-1.71)	0.34 (0.29-0.40)	0.61 (0.40-1.33)	0.55 (0.17-1.51)	0.47 (0.22-1.71)
Classical memory B cells %CD45 ⁺ cells Median (range)	0.52 (0.11-1.96)	0.25 (0.11-0.32)	0.74 (0.19-1.69)	0.55 (0.14-1.96)	0.45 (0.23-1.09)
Naïve B cells %CD45 ⁺ cells Median (range)	6.74 (1.16-13.06)	7.18 (1.27-11.92)	7.32 (4.60-13.06)	5.73 (1.16-8.42)	6.12 (3.78-10.77)
Non-switched memory B cells %CD45 ⁺ cells Median (range)	0.78 (0.19-2.68)	0.59 (0.19-0.88)	0.92 (0.21-2.68)	0.76 (0.32-1.60)	0.57 (0.19-1.44)
Plasma cells %CD45 ⁺ cells Median (range)	0.09 (0.01-1.79)	0.11 (0.03-0.35)	0.17 (0.04-0.63)	0.08 (0.01-1.79)	0.07 (0.01-0.80)
Transitional B cells %CD45 ⁺ cells Median (range)	1.53 (0.19-6.68)	2.43 (0.70-6.68)	2.06 (0.63-5.49)	0.96 (0.19-2.53)	1.09 (0.50-2.07)
CD16-CD56bright NK cells %CD45 ⁺ cells Median (range)	0.31 (0.01-1.04)	0.43 (0.06-0.84)	0.31 (0.03-0.92)	0.33 (0.01-1.04)	0.19 (0.01-0.47)
CD16+CD56bright NK cells %CD45 ⁺ cells Median (range)	0.10 (0.01-0.38)	0.07 (0.04-0.38)	0.15 (0.01-0.41)	0.07 (0.01-0.25)	0.08 (0.01-0.37)
CD16+CD56+ NK cells %CD45 ⁺ cells Median (range)	5.29 (0.01-18.38)	5.20 (0.21-9.10)	5.52 (0.01-13.72)	5.48 (1.72-12.74)	3.19 (0.01-18.38)
CD16-CD56+ NK cells %CD45 ⁺ cells Median (range)	0.36 (0.07-1.90)	0.38 (0.07-0.70)	0.36 (0.20-1.40)	0.36 (0.09-1.90)	0.35 (0.15-1.17)
NK-T cells %CD45 ⁺ cells Median (range)	1.08 (0.19-3.22)	0.27 (0.20-0.32)	1.11 (0.40-2.98)	0.80 (0.19-2.86)	1.47 (0.37-3.22)
CD8 TCM %CD45 ⁺ cells Median (range)	0.81 (0.01-6.44)	0.65 (0.01-1.06)	0.82 (0.21-6.44)	1.05 (0.17-3.30)	0.81 (0.43-2.34)

CD8 TN %CD45 ⁺ cells Median (range)	7.31 (0.04-19.47)	10.05 (0.04-13.60)	8.89 (3.38-19.47)	8.06 (1.36-13.11)	6.49 (1.97-9.57)
CD8 TEMRA %CD45 ⁺ cells Median (range)	1.45 (0.01-5.85)	0.61 (0.01-3.70)	2.56 (0.63-5.85)	1.30 (0.30-2.40)	1.39 (0.42-2.90)
CD8 TEM %CD45 ⁺ cells Median (range)	1.96 (0.02-26.52)	0.89 (0.01-2.15)	1.95 (0.40-26.52)	1.90 (0.23-4.35)	2.73 (1.06-5.01)
Activated Tregs %CD45 ⁺ cells Median (range)	1.06 (0.01-2.81)	1.47 (0.03-1.98)	1.38 (0.72-2.59)	1.05 (0.01-2.81)	0.77 (0.38-1.49)
Naive Tregs %CD45 ⁺ cells Median (range)	0.99 (0.02-3.73)	0.93 (0.02-1.45)	0.94 (0.34-1.54)	1.14 (0.12-3.73)	0.86 (0.44-2.36)
TFH cells %CD45 ⁺ cells Median (range)	1.53 (0.03-9.72)	1.37 (0.03-2.0)	1.76 (0.31-9.72)	1.21 (0.35-2.49)	1.50 (0.96-6.41)
CD4 Thelper cells %CD45 ⁺ cells Median (range)	4.51 (0.16-10.78)	3.66 (0.16-5.59)	3.82 (1.40-9.30)	4.96 (0.47-9.38)	6.28 (2.22-10.78)
CD4 TN %CD45 ⁺ cells Median (range)	13.82 (0.27-31.01)	18.83 (0.35-31.01)	16.47 (7.15-26.00)	13.25 (0.27-22.06)	9.56 (5.70-24.11)
CD4 TEMRA %CD45 ⁺ cells Median (range)	0.41 (0.01-1.44)	0.37 (0.01-0.61)	0.52 (0.09-1.44)	0.30 (0.02-1.19)	0.41 (0.04-0.70)
cDCs %CD45 ⁺ cells Median (range)	0.14 (0.02-0.66)	0.19 (0.04-0.49)	0.17 (0.04-0.66)	0.13 (0.02-0.40)	0.07 (0.02-0.21)
pDCs %CD45 ⁺ cells Median (range)	0.09 (0.01-0.29)	0.13 (0.06-0.22)	0.10 (0.03-0.22)	0.07 (0.01-0.29)	0.05 (0.02-0.20)
Non-classical monocytes %CD45 ⁺ cells Median (range)	0.22 (0.01-2.01)	0.23 (0.10-2.01)	0.27 (0.01-1.56)	0.22 (0.03-0.73)	0.11 (0.01-0.66)
Intermediate monocytes %CD45 ⁺ cells Median (range)	0.18 (0.01-2.99)	0.43 (0.14-2.99)	0.21 (0.01-1.61)	0.12 (0.03-0.36)	0.13 (0.01-0.95)
Classical monocytes %CD45 ⁺ cells Median (range)	1.85 (0.44-10.80)	3.04 (0.92-10.80)	1.68 (0.44-4.64)	1.72 (0.74-2.98)	1.90 (0.87-4.00)
ILCs %CD45 ⁺ cells Median (range)	0.83 (0.04-2.40)	0.69 (0.04-1.35)	0.94 (0.36-1.67)	1.09 (0.24-2.40)	0.71 (0.26-1.90)

560




Figure 1




Figure 2









Figure 3




Figure 4







Figure 5

A**B****C****Figure 6**